

## Regimen Reference Order – CUTA – trametinib + daBRAFeinib

ARIA: CUTA - [trametinib + daBRAFeinib]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Melanoma BRAF mutation positive, Metastatic

### **Proceed with treatment if:**

- *ANC equal to or greater than  $1.2 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$*
- *ALT less than 3 times the upper limit of normal*
- *Total bilirubin less than 2 times the upper limit of normal*
- *Creatinine clearance equal to or greater than 30 mL/minute*
  - ❖ **Contact Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – CUTA –trametinib + daBRAFeinib

Drug	Dose	CCMB Administration Guideline
trametinib	2 mg	Orally once daily on an empty stomach To be taken at the same time as morning dose of daBRAFeinib <b>(Self-administered at home)</b>
daBRAFeinib	150 mg	Orally twice daily on an empty stomach <b>(Self-administered at home)</b>
trametinib (MEKINIST®) available dosage strengths: 0.5 mg and 2 mg tablets Classification: Cytotoxic, Hazardous daBRAFeinib (TAFINLAR®) available dosage strengths: 50 mg and 75 mg capsules Classification: Cytotoxic, Hazardous		

### REQUIRED MONITORING

#### Cardiac monitoring

- EKG and Left Ventricular Ejection Fraction (LVEF) at baseline and every 3 to 6 months during treatment at the physician's discretion

#### All Cycles

- CBC, serum creatinine, liver enzymes, total bilirubin, electrolytes, and blood glucose as per Physician Orders
- Clinical skin toxicity and nail assessment
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation)

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

### INSTRUCTIONS FOR PATIENT

- Serious non-infectious fever can occur. Patients should be instructed to contact their cancer team if they develop any fever greater than **39.5 degrees Celsius** or any fever with chills
- trametinib and daBRAFeinib should be taken on an empty stomach with a glass of water at least one hour before or two hours after a meal
- Evening dose of daBRAFeinib should be taken approximately 12 hours after morning dose
- This regimen has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit or grapefruit juice
- trametinib is stored in the refrigerator. The desiccant should not be removed
- daBRAFeinib is stored at room temperature
- Reinforce applicable safe handling precautions of medications, blood and body fluids during trametinib and daBRAFeinib treatment

### ADDITIONAL INFORMATION

- Serious febrile drug reactions may occur and may be accompanied by severe rigors or chills, dehydration, hypotension or renal failure (in the absence of infection). Interruption of therapy and symptom management may be required to manage pyrexia
- This regimen can prolong QT interval and PR interval
- trametinib has been associated with interstitial lung disease and pneumonitis
- trametinib and daBRAFeinib have been associated with ocular toxicity
- trametinib and daBRAFeinib will be dispensed by CCMB Pharmacy